Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
WEBSep 16, 2024 · The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab), for...
Genentech: Press Releases | Friday, Sep 13, 2024
WEBSep 13, 2024 · Ocrevus Zunovo™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs. South San Francisco, CA -- September 13, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus ...
FDA approves Ocrevus Zunovo for relapsing and primary …
WEBSeptember 16, 2024. The U.S. Food and Drug Administration approved Ocrevus Zunovo for the treatment of relapsing and primary progressive multiple sclerosis. One of several patient-reported outcomes showed more than 92 percent of trial participants reported being satisfied with treatment administration. Ocrevus Zunovo is the only twice-a-year ...
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO …
WEBSep 13, 2024 · "We are pleased that the subcutaneous formulation of OCREVUS, OCREVUS ZUNOVO, which contains our ENHANZE drug delivery technology, is now approved in the U.S. for patients with these two forms...
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze …
WEBSep 16, 2024 · ROG.SW. HALO. Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics ...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a …
WEBSep 16, 2024 1:00am EDT. OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office. This approval is...
Genentech: News Features | FDA Approves the First and Only …
WEBOn September 13, 2024, the FDA approved Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in adults.
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO …
WEBSep 13, 2024 · "We are pleased that the subcutaneous formulation of OCREVUS, OCREVUS ZUNOVO, which contains our ENHANZE drug delivery technology, is now approved in the U.S. for patients with these two...
FDA Approves Ocrevus Zunovo™ | National MS Society
WEBSep 13, 2024 · Ocrevus Zunovo works in the body the same as Ocrevus. Its safety, efficacy, and side effect profile mirrors that of Ocrevus. The difference is in how the therapy is delivered: Ocrevus is given as an IV infusion which can take hours, while Ocrevus Zunovo is given as an HCP-administered SC injection over the course of …
FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis
WEBSep 13, 2024 · The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The approval marks the first and only twice yearly, health care professional-administrated subcutaneous (SC) injections for both forms of MS. 1
- Some results have been removed
Skip to content